Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study
The use of fixed-dose combinations for hypertension (HTN) has long been a routine clinical practice. Recently, special attention has been paid to multi-target fixed-dose combinations with the ability to reduce not only blood pressure (BP), but also low-density lipoprotein (LDL) levels. At the same time, there is not much evidence for this approach. Aim . To evaluate the antihypertensive and lipid-lowering effect of fixed-dose combinations based on perindopril. Material and methods . The INTEGRATION II study included 9777 patients (mean age 61,8±9,8 years) with HTN and dyslipidemia (DLP), who were prescribed a fixeddose antihypertensive combination of perindopril+amlodipine+indapamide (Co-Dalneva®) in combination with rosuvastatin (Roxera®) (n=5128) or a multi-target fixed-dose combination of perindopril+indapamide+rosuvastatin (Roxatenz-inda) (n=4649). Results . In the Co-Dalneva® + Roxera® group, a decrease in systolic BP from 164,9±13,8 mm Hg to 127,2±8,8 mm Hg was noted over 12‑week treatment, diastolic BP — from 94,2±10,0 mm Hg to 77,6±6,3 mm Hg; total cholesterol level decreased from 6,2±1,1 mmol/l to 4,3±0,8 mmol/l, and LDL level — from 3,6±1,0 mmol/l to 2,1±0,7 mmol/l. In the Roxatenz-inda group, over the same period, systolic BP decreased from 161,9±12,7 mm Hg to 126,2±8,3 mm Hg, while diastolic BP — from 94,5±9,5 mm Hg to 76,9±6,8 mm Hg. The total cholesterol level decreased from 6,3±1,1 mmol/l to 4,4±0,8 mmol/l; the LDL level — from 3,5±1,0 mmol/l to 2,1±0,6 mmol/l. Both physicians and patients rated Likert scale satisfaction with therapy as very good (4,75-4,8 out of 5), while the compliance according to the patient corresponds to high and highest. Conclusion . The results of the INTEGRATION II study demonstrated the efficacy and convenience of fixed-dose combinations of antihypertensive and lipid-lowering agents based on perindopril and rosuvastatin in practice. There are good tolerability and a high level of satisfaction with the treatment from both the patient’s and the phusician’s perspective.
Authors
- А. О. Недошивин (ORCID: https://orcid.org/0000-0001-8892-6411)
Institutions
- Federal Almazov North-West Medical Research Centre (RU)
Publication Details
- Journal
- Russian Journal of Cardiology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.15829/1560-4071-2025-6418
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00